Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 16/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 16/20 | 0.39 |
| ▸ | ITGAL | P20701 | 16/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30267904 | 0.81 | POLB (0.34) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL18990257 | 0.81 | POLB (0.34) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL18990256 | 0.81 | POLB (0.34) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20535491 | 0.80 | ALDH1A1 (0.39) | ITGALMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20535493 | 0.80 | ALDH1A1 (0.39) | ITGALMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20535775 | 0.80 | ICAM1 (0.31) | ICAM1ITGALALDH1A1HTT | |
| SCHEMBL20535776 | 0.80 | ICAM1 (0.31) | ICAM1ITGALALDH1A1HTT | |
| SCHEMBL23702353 | 0.79 | KDM4E (0.33) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL23702352 | 0.79 | KDM4E (0.33) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL24113456 | 0.79 | MAPT (0.38) | MEN1ALDH1A1MAPTKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | ITGB2 2479/4885ICAM1 3963/4885ITGAL 4154/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | ITGB2 2802/4885ICAM1 4540/4885ITGAL 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.